INTRODUCTION {#sec0005}
============

Cerebral small vessel disease (cSVD) is the umbrella term for a range of abnormalities of the small vessels of the brain, including arterioles, capillaries, and venules \[[@ref001]\]. Individual neuroimaging markers of cSVD include lacunes, white matter hyperintensities (WMH), cerebral microbleeds (CMB), and enlarged perivascular spaces (ePVS) in the basal ganglia. These markers likely share similar pathology and are common, often asymptomatic, findings on magnetic resonance imaging (MRI) in older people \[[@ref002]\]. Clinically, they are associated with an increased risk of stroke, gait disturbances,and cognitive decline \[[@ref004]\]. It is postulated that cSVD pathology contributes to up to 45% of all dementia cases \[[@ref005]\].

While the exact pathogenesis of cSVD is still unclear, it is evident that cardiovascular health plays an important role. Hypertension is associated with each individual marker of cSVD \[[@ref007]\]. High blood pressure (BP) is thought to affect brain health by causing structural changes to the cerebral microvasculature that lead to endothelial dysfunction, increased permeability of the blood-brain barrier and dysregulation of cerebral blood flow \[[@ref011]\]. Clinically, it is evident that hypertension during midlife is a risk factor for developing dementia \[[@ref013]\]. However, several ambiguities remain. For example, contradictions exist on the role of BP in older people who already present with some degree of cognitive impairment \[[@ref014]\], and on the effect of BP lowering in order to reduce dementia risk \[[@ref015]\]. The conflicting findings regarding mean BP level make a case for looking beyond the use of BP as a static measurement only and for taking into account the dynamic aspects of BP.

Within the cardiovascular field there is increasing attention to study the prognostic significance of BP variability (BPV) in relation to adverse health outcomes and organ damage, including the brain \[[@ref016]\]. High BPV is associated with stroke and transient ischemic attack, mortality, and cardiovascular outcomes \[[@ref017]\]. There is limited information on BPV and cSVD markers, other than WMH \[[@ref020]\], but it is hypothesized that high fluctuations in BP put more stress on vessel walls than high BP only, accelerating the hypertension-cSVD pathology cascade.

It is likely that the causes and consequences of high BPV depend on which timeframe is investigated \[[@ref022]\]. Previous studies reporting an association between BPV and markers of cSVD focused on either long-term BPV, based on consecutive BP measurements performed over multiple office visits in a period of months or years, or on short-term BPV, based on 24-h ambulatory BP measurements (ABPM) with a 15--30 min interval. Home BP measurements (HBPM), taken in the morning and evening over a week, have the advantage of providing information on the consistency of BP control on a day-to-day basis \[[@ref023]\], but have not been widely studied in association with cSVD burden \[[@ref024]\].

The majority of the previous studies on BPV and cSVD focused on only one marker of cSVD. Co-occurrence of different markers of cSVD is associated with decreased cognitive function, indicating that the markers have additive effects when present together \[[@ref027]\]. The 'total cSVD score' combines the individual markers into one score to reflect overall burden \[[@ref028]\]. This score has been associated with reduced cognitive function in a memory clinic population \[[@ref029]\], a population in which substantial burden of cSVD is expected.

Taken together, this study adds to previous work by assessing the association between BPV determined on a day-to-day basis, using HBPM, and the total burden of cSVD. Specifically, the aim of this study was to investigate the cross-sectional association between day-to-day BPV and total cSVD score in older people attending a memory clinic.

METHODS {#sec0010}
=======

Study design and participants {#sec0015}
-----------------------------

In this cross-sectional study, we included a convenience sample made up of people aged \>50 years who were referred to the memory clinic of the Radboud university medical center (Nijmegen, The Netherlands). Inclusion lasted from January 2014 until December 2018. In order to be eligible, participants should have performed HBPM and had a cerebral MRI scan as part of their diagnostic assessment. At the end of their first visit to the memory clinic, participants were asked to perform HBPM by their clinician or nurse. Whether an MRI scan was deemed necessary for diagnosis was decided in a multidisciplinary meeting. For example, when the diagnosis was already clear from the clinical information available, an MRI was not performed. This was based on previous research in our memory clinic on the added diagnostic value of MRI \[[@ref030]\]. In the inclusion period, a total of 1,310 patients were seen at the memory clinic, 327 of whom had an MRI performed. Thirty-five percent of this group also performed HBPM. Participants with a clinical history of stroke or who were diagnosed with a neurological condition other than a neurodegenerative disease were excluded from the current analyses. The study was submitted to the Medical Ethics Committee (CMO Arnhem-Nijmegen) and was exempt from formal approval because the study did not fall within the remit of the "Medical Research Involving Human Subjects Act". The study was also exempt from the need to obtain explicit written informed consent, because of the low additional burden of HBPM. Despite this, oral informed consent was asked from each participant and, if applicable, their caregiver.

Day-to-day blood pressure variability {#sec0020}
-------------------------------------

Participants performed HBPM using a validated, memory-equipped, automatic oscillometric device (Microlife WatchBP Home, Microlife, Heerbrugg, Switzerland) \[[@ref031]\], following an international recommended protocol \[[@ref032]\]. They received oral and written instructions and on how to perform HBPM and could be aided by their caregiver (if available). The protocol comprised duplicate measurements in the morning (5.00--11.00 am) and evening (5.00--11.00 pm) for 7 consecutive days, resulting in a maximum of 28 measurements. Measurements of day 1 were discarded and duplicate measurements were averaged, to reduce variation resulting from random or measurement error. A minimum of 8 (out of 12) measurements was set as a requirement to be included in the analysis. For separate analysis of morning and evening measurements, 4 (out of 6) was the minimum required number of measurements. Day-to-day BPV was defined as the within-subject coefficient of variation (CV) of both systolic (SBP) and diastolic blood pressure (DBP), calculated by dividing the standard deviation (SD) with the mean (CV = SD/mean\*100%).

Total cerebral small vessel disease score {#sec0025}
-----------------------------------------

Participants were scanned with either of two scanners, Magnetom Avanto, Siemens Healthcare (1.5T) or Magnetom Prisma, Siemens Healtcare (3.0T). The scan protocol included T1-weighted, T2-weighted, fluid-attenuated inversion recovery (FLAIR) and susceptibility-weighted imaging (SWI) or T2\*-weighted gradient-echo (GRE) sequences. Details of the scan parameters are provided in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. The total cSVD score consisted of a previously described four-point scale \[[@ref028]\], including presence of WMH, CMB, lacunes, and ePVS in the basal ganglia ([Fig. 1](#jad-74-jad191134-g001){ref-type="fig"}). Two trained clinicians rated WHM severity and presence of CMBs (AH, MT). WMH severity was rated on FLAIR images using the Fazekas scale \[[@ref033]\]. One point was added to the cSVD score in case of severe WMH, defined as periventricular WMH Fazekas grade 3 or deep WMH Fazekas grade 2 or 3. CMBs were rated on the SWI or T2^\*^ GRE images using the Microbleed Anatomical Rating Scale \[[@ref034]\]. One point was added to the cSVD score if one or more microbleeds were present. Interrater kappa was *κ*= 0.90 for presence of severe WMH and *κ*= 0.66 for presence of CMBs. Lacunes of presumed vascular origin were identified using FLAIR, T1-, and T2-weighted images by two raters (RH, SR). They were defined according to STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) criteria, as subcortical, round or ovoid shaped, fluid-filled cavities, 3--15 mm in diameter \[[@ref001]\]. The presence of one or more lacunes resulted in one extra point on the cSVD score. ePVS in the basal ganglia were assessed using FLAIR and T2-weighted images using the protocol of Doubal et al. (by RH, SR) \[[@ref035]\]. One point was added to the cSVD score if \>10 ePVS were visible in the basal ganglia on one side of the brain. Interrater kappa for presence of lacunes and for \>10 ePVS was *κ*= 0.63 and *κ*= 0.75, respectively. In case of disagreement on any of the markers, a third rater (JC) assessed the images in order to achieve consensus. All rating was performed blinded to clinical details.

![Construction of the total cerebral small vessel disease score. One point is added to the score in case of presence of: severe WMH (periventricular Fazekas grade 3 or deep Fazekas grade ≥2); ≥1 cerebral microbleed; \>10 perivascular spaces visible in the basal ganglia on at least one side of the brain; ≥1 lacune. WMH, white matter hyperintensities.](jad-74-jad191134-g001){#jad-74-jad191134-g001}

Clinical assessment {#sec0030}
-------------------

Additional information on descriptives and covariates was extracted from the patient's medical record and included age, gender, education, medical history, current medication use, body mass index (BMI), smoking status, office BP, and cognitive diagnosis. Office BP was measured in supine position using a manual sphygmomanometer. Cardiovascular history was marked as present if one of the following conditions were identified in the medical history of the patients' health record: chronic heart failure, coronary heart disease, arrhythmia, or peripheral artery disease. The cognitive diagnosis was based on all information from the geriatric assessment, including the cerebral MRI, and was established in a multidisciplinary meeting with geriatricians and neuropsychologists using international criteria \[[@ref036]\]. For descriptive purposes, we categorized participants into four groups: dementia (mild stage, any type), mild cognitive impairment, subjective cognitive impairment, and other diagnoses (i.e., psychiatric disorder).

Statistical analyses {#sec0035}
--------------------

Characteristics are presented as mean and standard deviation for continuous variables and percentage and frequency for categorical variables. The total cSVD score was used as an ordinal variable. Similar to previous work \[[@ref038]\], cSVD scores of 3 and 4 were combined because each score had only few cases (*n* = 16 and *n* = 7, respectively), resulting in a maximum score of 3. Analysis of variance and chi-squared tests were used to compare characteristics by cSVD score. Ordinal logistic regression was used to investigate if indices of home BP were associated with cSVD score. The proportional odds assumption was checked through the test of parallel lines and no violations were identified. BP indices that were assessed were CV and mean of SBP and DBP. In the first model we adjusted for age and sex. In the second model, we additionally adjusted for current smoking, diabetes, use of antihypertensive medication and history of cardiovascular diseases (CVD). Since we found no evidence for multicollinearity between mean and CV of home BP (variance inflation factors all \<1.05), we fitted a third model in which CV and mean BP were simultaneously added as predictors. All models were run separately for morning and evening BP indices. Additionally, we explored associations of BP indices with a dichotomized cSVD score (0 versus 1--4) and with individual markers of cSVD, using logistic regression analyses. Odds ratio's (OR) with 95% confidence intervals (CI) are reported. For CV, OR are reported per unit increase. For mean BP, OR are reported per 10 (systolic) or 5 (diastolic) mmHg increase. All analyses were performed using IBM SPSS Statistics 25.0 (SPSS, Inc., Chicago, IL, USA).

RESULTS {#sec0040}
=======

Characteristics {#sec0045}
---------------

In total, 104 participants met the inclusion criteria. Fifteen participants were excluded because of invalid HBPM data (too few measurements) and seven because of insufficient MRI quality, leaving 82 participants enrolled in the analysis. Mean age of the study population was 71.2±7.9 years and 34% (*n* = 28) were female. Dementia (mild stage) was diagnosed in 46% (*n* = 38), mild cognitive impairment in 34% (*n* = 28), and 17% (*n* = 14) were classified as having subjective memory complaints. In addition, two participants were diagnosed with a depression.

Twenty-two percent of the sample had no markers of cSVD, 24% had one marker, 26% had two markers, and 28% had three or four markers. [Supplementary Figure 1](#S1){ref-type="supplementary-material"} shows the occurrence of combinations of cSVD markers. The cSVD score did not differ between the different MR scanners ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). Characteristics of the total sample and according to cSVD score are presented in [Table 1](#jad-74-jad191134-t001){ref-type="table"}. Age increased with increasing cSVD score (*p* \< 0.001). The prevalence of dementia increased with increasing cSVD scores, with a prevalence of 28% in those with cSVD score of 0, compared to 74% in those with cSVD score of 3/4 (*p* = 0.039).

###### 

Characteristics of the total study sample and according to cSVD score

  Variable                       Total      cSVD 0      cSVD 1      cSVD 2     cSVD 3/4    ^\*^*p*-value
  --------------------------- ----------- ----------- ----------- ----------- ----------- ---------------
  n                               82          18          20          21          23      
  Age (y)                      71.2±7.9    64.7±7.8    68.9±5.5    73.6±5.6    76.2±7.6       \<0.001
  Sex (% female)               28 (34.1)   5 (27.8)    7 (35.0)    9 (42.9)    7 (30.4)        0.758
  Living with spouse (%)       60 (73.2)   14 (77.8)   18 (90.0)   12 (57.1)   16 (69.6)       0.113
  Education (y)                11.0±2.8    10.9±2.8    11.7±2.8    11.6±3.4    11.3±2.9        0.771
  BMI (kg/m^2^)^\*\*^          25.7±4.1    27.3±5.4    27.1±4.2    23.8±3.2    24.9±3.0        0.031
  History of CVD (%)           24 (29.3)   8 (44.4)    7 (35.0)    5 (23.8)    4 (17.4)        0.242
  Diabetes (%)                 10 (12.2)   2 (11.1)     1 (5.0)     1 (4.8)    6 (26.1)        0.102
  Current smoking (%)          12 (14.6)   4 (22.2)        0       5 (23.8)    3 (13.0)        0.126
  Antihypertensives (%)        40 (48.8)   10 (55.6)   8 (40.0)    8 (38.1)    14 (60.9)       0.354
  Diagnosis (%)                                                                                0.039
    Dementia                   38 (46.3)   5 (27.8)    6 (30.0)    10 (47.6)   17 (73.9)  
    MCI                        28 (34.1)   7 (38.9)    7 (35.0)    10 (47.6)   4 (17.4)   
    SCI                        14 (17.1)   5 (27.8)    6 (30.0)     1 (4.8)     2 (8.7)   
    Other                       2 (2.4)     1 (5.6)     1 (5.0)        0           0      
  MR scanner (% 3T)^\*\*\*^    32 (39.0)   6 (33.3)    8 (40.0)    9 (42.9)    9 (39.1)        0.944
  CSVD markers (%)                                                                              --
    Lacune(s)                  27 (32.9)      --       2 (10.0)    6 (28.6)    19 (82.6)  
    WMH                        40 (48.8)      --       5 (25.0)    14 (66.7)   21 (91.3)  
    CMB                        26 (31.7)      --       5 (25.0)    4 (19.0)    17 (73.9)  
    ePVS                       45 (54.9)      --       8 (40.0)    18 (85.7)   19 (82.6)  

Results are presented as mean±standard deviation or number (frequency). cSVD, cerebral small vessel disease; BMI, body mass index; CVD, cardiovascular disease; MCI, mild cognitive impairment; SCI, subjective cognitive impairment; WMH, white matter hyperintensities; CMB, cerebral microbleeds; ePVS, enlarged perivascular space. ^\*^ Resulting from univariate analysis of variance (continuous variables) or chi-square test (categorical variables). ^\*\*^Available for *n* = 69. ^\*\*\*^Those not scanned on the 3T scanner were scanned on the 1.5T scanner.

Blood pressure (variability) and cSVD score {#sec0050}
-------------------------------------------

Mean home BP was 140/79±15/9 mmHg, while office BP was 160/85±19/10 mmHg. Univariate analyses, presented in [Table 2](#jad-74-jad191134-t002){ref-type="table"}, showed that SBP was lowest in the group without cSVD burden and highest in the group with highest cSVD burden (*p* \< 0.001 for home SBP, *p* = 0.015 for office SBP). The same trend was observed for DBP, but this was not statistically significant (*p* = 0.294 for home DBP, *p* = 0.074 for office DBP).

###### 

Blood pressure values of the total study sample and according to cSVD score

  Variable                   Total        cSVD 0       cSVD 1       cSVD 2      cSVD 3/4     \*p
  ----------------------- ------------ ------------ ------------ ------------ ------------ -------
  Office BP                                                                                
    SBP (mmHg)             159.6±19.2   148.9±19.0   155.6±22.8   164.4±11.9   166.9±17.5   0.015
    DBP (mmHg)             84.6±10.1     80.8±9.7    82.1±10.4     85.8±9.3     88.4±9.8    0.074
  Home BP                                                                                  
    Readings (nr)^\*\*^     21.7±2.9     22.0±2.5     20.8±2.8     22.4±2.2     21.5±3.8    0.347
    Hypertension (%)       49 (59.8)     6 (33.3)    17 (85.0)     9 (42.9)    17 (73.9)    0.002
    SBP (mmHg)             139.7±14.6   131.3±14.3   145.1±12.0   134.6±11.0   146.4±15.2   0.001
    DBP (mmHg)              79.1±8.8     76.9±8.0     81.5±7.4     77.4±8.1    80.3±10.8    0.294
    CV SBP (%)              7.1±2.2      5.7±1.4      7.3±2.5      7.3±2.1      7.7±2.2     0.017
    CV DBP (%)              7.3±2.7      6.1±1.6      8.0±3.2      7.3±2.6      7.8±2.9     0.125
  Morning BP                                                                               
    SBP (mmHg)             139.7±15.2   131.0±14.5   146.9±13.5   133.8±10.6   145.6±15.8   0.001
    DBP (mmHg)              80.0±9.3     77.8±8.0     83.2±8.4     78.3±8.3    80.4±11.2    0.249
    CV SBP (%)              5.9±2.3      4.6±1.9      6.2±2.7      6.1±2.4      6.4±2.0     0.057
    CV DBP (%)              5.9±3.0      5.2±1.8      7.1±4.4      5.4±2.6      5.8±2.3     0.185
  Evening BP                                                                               
    SBP (mmHg)             139.9±15.1   131.5±14.8   141.5±12.2   136.4±12.8   149.0±15.2   0.001
    DBP (mmHg)              78.3±8.9     76.0±8.5     78.5±7.0     77.3±8.7    81.2±10.6    0.292
    CV SBP (%)              7.2±2.9      6.0±2.0      6.5±2.7      7.2±3.0      8.6±3.3     0.033
    CV DBP (%)              7.0±3.7      5.7±2.7      6.9±2.2      7.0±3.5      8.2±5.1     0.211

Results are presented as mean±standard deviation. cSVD, cerebral small vessel disease; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; CV, coefficient of variation. ^\*^ Resulting from univariate analysis of variance. ^\*\*^After removal of day 1. Maximum value 24.

[Figure 2](#jad-74-jad191134-g002){ref-type="fig"} shows the individual data points for systolic and diastolic CV by cSVD burden. Univariate analyses showed that there was a difference between the systolic CVs of the cSVD groups (*p* = 0.017). The diastolic CV was marginally different between groups (*p* = 0.125). [Table 3](#jad-74-jad191134-t003){ref-type="table"} present the results from the multivariable ordinal regression models. Systolic CV was associated with cSVD burden (OR = 1.32, 95% CI = 1.07--1.63, *p* = 0.010), after adjustment for age, sex, current smoking, diabetes, use of antihypertensive medication and history of CVD. This association remained significant when we additionally adjusted for mean systolic BP (OR = 1.29, 95% CI = 1.04--1.60, *p* = 0.022). Diastolic CV and mean BP were not associated with cSVD burden ([Table 3](#jad-74-jad191134-t003){ref-type="table"}).

![Individual data points for systolic and diastolic CV by total cSVD score. Error bars present 95% confidence interval. *p*-value from univariate analysis of variance is 0.017 for systolic CV and 0.125 for diastolic CV. BP, blood pressure; CV, coefficient of variation; cSVD, cerebral small vessel disease.](jad-74-jad191134-g002){#jad-74-jad191134-g002}

###### 

Associations of total small vessel disease score with mean and coefficient of variation of home blood pressure

  Predictor         Model 1                     Model 2                     Model 3       
  ----------- ------------------- ------- ------------------- ------- ------------------- -------
  Mean SBP     1.32 (0.98--1.77)   0.066   1.28 (0.94--1.73)   0.114          --            --
  CV SBP       1.24 (1.02--1.52)   0.034   1.32 (1.07--1.63)   0.010   1.29 (1.04--1.60)   0.022
  Mean DBP     1.19 (0.93--1.53)   0.169   1.16 (0.89--1.49)   0.273          --            --
  CV DBP       1.11 (0.95--1.30)   0.176   1.10 (0.94--1.29)   0.234   1.09 (0.93--1.28)   0.286

Results from ordinal logistic regression. Model 1: adjusted for age and sex. Model 2: model 1 + current smoking, diabetes, use of antihypertensive medication and cardiovascular history. Model 3: model 2 + mean BP (systolic or diastolic). For mean BP, the OR is presented per 10 (systolic) or 5 (diastolic) mmHg increase. SBP, systolic blood pressure; DBP, diastolic blood pressure; OR, odds ratio; CI, confidence interval; CV, coefficient of variation.

As already suggested by [Fig. 2](#jad-74-jad191134-g002){ref-type="fig"}, pairwise comparisons in the univariate analyses showed that those with no cSVD burden had a lower systolic CV compared to those with a cSVD score of 1, 2, or 3, without differences between the latter three groups ([Supplementary Table 3](#S1){ref-type="supplementary-material"}). Therefore, logistic regression analyses were performed comparing presence versus absence of cSVD burden. After adjustment for age, sex, current smoking, diabetes, antihypertensive medication, and history of CVD both systolic and diastolic CV were associated with presence of cSVD (systolic: OR = 2.51, 95% CI = 1.21--5.18, *p* = 0.013; diastolic: OR = 1.48, 95% CI = 1.03--2.13, *p* = 0.036). These associations remained significant when we additionally adjusted for mean BP. See [Supplementary Table 4](#S1){ref-type="supplementary-material"} for the results from all logistic regression models. [Supplementary Table 5](#S1){ref-type="supplementary-material"} presents the associations between BP parameters and the individual cSVD markers. All markers were individually associated with higher BPV.

Morning and evening blood pressure (variability) {#sec0055}
------------------------------------------------

Paired samples-t-test showed that BPV was higher in the evening compared to morning, for both systolic CV (mean difference = 1.3, 95% CI = 0.6--2.1, *p* \< 0.001) and diastolic CV (mean difference = 1.2, 95% CI = 0.2--2.2, *p* = 0.025). Separate regression analyses for morning and evening BP are presented in [Table 4](#jad-74-jad191134-t004){ref-type="table"}. Evening systolic CV (OR = 1.31, 95% CI = 1.09--1.58, *p* = 0.004) was associated with total cSVD score. Morning CV was not associated with total cSVD score. Mean evening SBP was associated with cSVD burden (OR per 10 mmHg increase in SBP = 1.42, 95% CI = 1.03--1.95, *p* = 0.034).

###### 

Association of total small vessel disease score with mean and coefficient of variation of morning and evening home blood pressure

  Predictor                      Model 1                     Model 2                     Model 3       
  ------------- ---------- ------------------- ------- ------------------- ------- ------------------- -------
  Morning        Mean SBP   1.26 (0.95--1.65)   0.107   1.23 (0.92--1.67)   0.156          --            --
                  CV SBP    1.14 (0.95--1.36)   0.171   1.18 (0.98--1.42)   0.081   1.16 (0.96--1.40)   0.126
                 Mean DBP   1.14 (0.90--1.44)   0.256   1.11 (0.87--1.43)   0.367          --            --
                  CV DBP    1.01 (0.88--1.16)   0.875   1.01 (0.88--1.16)   0.918   1.00 (0.87--1.15)   0.995
  Evening^\*^    Mean SBP   1.49 (1.08--2.03)   0.013   1.42 (1.03--1.95)   0.034          --            --
                  CV SBP    1.23 (1.05--1.44)   0.011   1.31 (1.10--1.57)   0.003   1.31 (1.09--1.58)   0.004
                 Mean DBP   1.32 (1.01--1.73)   0.048   1.25 (0.95--1.66)   0.113          --            --
                  CV DBP    1.16 (1.01--1.33)   0.033   1.15 (0.99--1.33)   0.051   1.15 (0.99--1.32)   0.062

Results from ordinal logistic regression. Model 1: adjusted for age and sex. Model 2: model 1 + current smoking, diabetes, use of antihypertensive medication and cardiovascular history. Model 3: model 2 + mean BP (systolic or diastolic). For mean BP, the OR is presented per 10 (systolic) or 5 (diastolic) mmHg increase. OR, odds ratio; CI, confidence interval; CV, coefficient of variation. ^\*^*n* = 79, because of 3 participants with \<4 duplo measurement in the evening.

DISCUSSION {#sec0060}
==========

In this cross-sectional study, we investigated the association between day-to-day BPV and total cSVD burden on MRI, in older adults who attended our memory clinic for cognitive evaluation. We found that higher systolic BPV was a risk factor for cSVD burden, after controlling for several confounders and mean SBP. Diastolic BPV or mean BP were not associated with cSVD burden. There does not seem to be a dose-response relationship between BPV and cSVD burden in these cross-sectional analyses, as no differences in BPV between scores of 1, 2, and 3/4 were observed. When we separately calculated BPV for morning and evening measurements, only BPV in the evening was associated with the total cSVD score. This is, to the best of our knowledge, the first study investigating the association between BPV within a 1-week timeframe and total burden of cSVD.

Previous studies have mainly focused on the association between individual markers of cSVD and mainly measured BPV within other timeframes, i.e., from visit-to-visit or within 24-h. For example, several studies reported an association between WMH severity or progression and visit-to-visit BPV in healthy older adults \[[@ref021]\]. Only Yang et al. (2018) have reported the total cSVD score in relation to BPV \[[@ref026]\]. These authors found that higher 24-h BPV was associated with cSVD burden in a healthy sample with a mean age of 68 years. Regarding day-to-day BPV, this has previously been linked to cognitive decline and progression of WMH in healthy people aged 80 years or older, with a mean MMSE of 25 and a low level of morbidities \[[@ref024]\]. In two Japanese studies, the Hisayama study and Ohasama study, day-to-day BPV was associated with risk of dementia and cognitive decline, respectively \[[@ref040]\]. We recently showed both visit-to-visit and day-to-day BPV were related to clinical progression of Alzheimer's disease \[[@ref042]\], although for visit-to-visit BPV this was not replicated in another dementia cohort \[[@ref043]\]. In the Maastricht study, a composite score comprising 24-h and day-to-day BPV was associated with cognitive performance \[[@ref044]\]. The current study adds to the previous work on day-to-day BPV, by providing evidence for the potential underlying mechanism linking BPV and cognition. Although not completely understood, the pathophysiological mechanism between BPV and cSVD might involve a higher degree of mechanical stress on vessel walls leading to endothelial injury, arterial stiffness, and ischemic hypoperfusion. A bidirectional association is also plausible, i.e., cSVD may be associated with neurodegenerative changes to cortical structures that are involved in central control of BP and heart rate, leading to high BPV \[[@ref045]\].

Determinants of BPV are still under investigation, but it is likely that these differ between different measurement methods and timeframes of BPV \[[@ref022]\]. This idea is strengthened by the observation that there is only a very weak correlation between visit-to-visit, 24-h and day-to-day BPV \[[@ref046]\]. Short-term variability seems mainly determined by physiological mechanisms, including the baroreflex, humoral factors, and the circadian rhythm. For long-term variability, behavioral factors, compliance to antihypertensive treatment and seasonal changes are involved as well. Despite these differences, all types of BPV have now been linked to cSVD. Given the challenges in determining visit-to-visit BPV, which requires multiple clinic visits, and the preference of older people with cognitive impairment for HBPM over 24-h BP measurements \[[@ref047]\], day-to-day BPV may be a more feasible approach to assess BPV in relation to cognition and cSVD.

In our study, BPV was lower in the morning compared to the evening. This has been reported before \[[@ref048]\]. When we differentiated between morning and evening BP values, only BP and BPV in the evening were associated with cSVD. Lower within-subject variation in morning measurements can be expected, given that these are less affected by physical activity, stress, and other factors that are more likely to occur during the course of the day. Also, circumstances of the measurement taken in the morning are potentially more standardized (after waking up, but before medication intake and breakfast) than in the evening (before or at least 1 h after dinner, after taking 5 min of rest) \[[@ref049]\]. It might therefore be the case that the range of morning BPV was too small to detect significant associations with cSVD.

This study has several strengths and limitations. Compared to previous studies on BPV and cSVD, we had a relatively small sample size. However, we were able to study a combination of four markers of cSVD instead of focusing on one or two and we studied BPV from day-to-day. Our study population was based on older people referred to a memory clinic. This comprises a group in which (subjective) cognitive impairment is present and who have different diagnoses and mixed pathologies. The use of convenience sample might have introduced selection bias and limits generalizability. Moreover, only patients in whom an MRI was deemed informative for clinical decision making were included and patients had to be willing and able to perform HBPM. We used international criteria for the assessment of cSVD markers, with moderate to excellent interrater agreement \[[@ref001]\]. Although the total cSVD score as proposed by Staals and colleagues is a valid measure to estimate total brain damage on MRI, the content validity of the scale might be improved by taking into account location and number of individual markers \[[@ref028]\]. A limitation of the current study is the use of two MR scanners. Although this may have been a source of bias, the mean cSVD scores were similar ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). In addition, this is more likely to represent clinical reality.

In conclusion, we found that BPV from day-to-day was associated with cSVD burden, independent from mean BP, in older people attending a memory clinic. This study provides the field with new information regarding BPV and cSVD. Future longitudinal studies in a population-based sample are warranted to assess the effect of day-to-day BPV on progression of cSVD and the potential of modifying day-to-day BPV in order to reduce cSVD progression.
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###### Supplementary Material
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Click here for additional data file.
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